openPR Logo
Press release

Multiple System Atrophy Pipeline Insight 2025: 22+ Pipeline Drugs, Disease-Modifying Candidates, and Symptomatic Therapies Advancing Clinical Care | DelveInsight

09-17-2025 01:56 PM CET | Health & Medicine

Press release from: DelveInsight

Multiple System Atrophy Pipeline Insight

Multiple System Atrophy Pipeline Insight

DelveInsight's "Multiple System Atrophy (MSA) - Pipeline Insight, 2025" reviews a growing portfolio of 22+ therapies in development for MSA, a rare, rapidly progressive neurodegenerative disorder characterized by autonomic failure, Parkinsonism, and cerebellar dysfunction. With no approved disease-modifying treatments and a high unmet need for therapies that slow progression or meaningfully improve function, MSA remains a critical focus area in movement disorders research.

The MSA pipeline spans disease-modifying strategies (including anti-alpha-synuclein antibodies and small molecules that target protein aggregation), neuroprotective agents aimed at mitochondrial or lysosomal function, and symptomatic therapies addressing autonomic dysfunction, orthostatic hypotension, and motor impairment. Cell- and gene-based approaches, as well as drug-repurposing programs, are also being explored to accelerate development timelines. Biomarker and imaging advances are enabling better patient selection and earlier trial readouts, crucial for a condition with a heterogeneous clinical presentation.

Several programs have progressed into mid-stage studies, reflecting intensified investment and collaborative efforts between biotech, academic centers, and consortia. As trial designs mature and biomarkers improve, the MSA landscape is shifting from supportive care toward targeted, mechanism-based interventions that could alter disease trajectory and patient outcomes.

DelveInsight's Multiple System Atrophy - Pipeline Insight, 2025 provides a concise assessment of clinical candidates, mechanism-of-action trends, and competitive positioning-offering stakeholders actionable intelligence on a pipeline that holds promise to transform care for people living with MSA.

Interested in learning more about the current treatment landscape and the key drivers shaping the multiple system atrophy pipeline? Click here: https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Multiple System Atrophy Pipeline Report
• DelveInsight's multiple system atrophy pipeline analysis depicts a strong space with 20+ active players working to develop 25+ pipeline drugs for multiple system atrophy treatment.
• The leading multiple system atrophy companies include Theravance Biopharma, Alterity Therapeutics, AskBio, Kainos Medicines, CORESTEM, Inc., ProMIS Neuroscience, H. Lundbeck A/S, and others are evaluating their lead assets to improve the Multiple System Atrophy treatment landscape.
• Key multiple system atrophy pipeline therapies in various stages of development include Ampreloxetine, ATH434, AB-1005, KM-819, Lu AF82422, CE111BR16, PMN442, and others.
• In September 2025, Teva Pharmaceutical (NYSE:TEVA) announced that its investigational MSA treatment, emrusolmin, received Fast Track designation from the U.S. FDA. The drug is currently in Phase 2 development for Multiple System Atrophy.
• In August 2025, Tiziana Life Sciences received FDA clearance of its IND for a Phase 2a trial of intranasal foralumab in patients with Multiple System Atrophy (MSA), a rare neurodegenerative disease with no approved therapies. The six-month open-label study will evaluate microglial activation, clinical outcomes, and safety of the fully human anti-CD3 monoclonal antibody delivered via nasal spray.
• In July 2025, NKGen Biotech received FDA authorization for an Expanded Access Program (EAP) to use its NK cell therapy, troculeucel, in multiple neurodegenerative diseases-including Alzheimer's, Parkinson's, ALS, MSA, PSP, FTD, MS, and Lewy Body Dementia-beyond its current Phase 2a trial in moderate-stage Alzheimer's disease.
• In May 2025, Alterity Therapeutics announced that the FDA granted Fast Track designation for ATH434, its investigational treatment for Multiple System Atrophy (MSA). This designation aims to expedite the development and review of ATH434, recognizing its potential to address the significant unmet need in MSA, a condition currently without an approved therapy.
• In February 2025, Alterity Therapeutics' ATH434 showed promising Phase 2 results in a randomized, double-blind trial for early-stage multiple system atrophy (MSA). The treatment, particularly at a 50 mg dose, was well-tolerated and demonstrated both clinical and biomarker-based benefits.

Request a sample and discover the recent breakthroughs happening in the multiple system atrophy pipeline landscape at https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Multiple System Atrophy Overview
Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder that affects the autonomic nervous system and movement. It is characterized by a combination of symptoms, including motor dysfunction, autonomic failure (such as blood pressure issues, bladder problems, and difficulty breathing), and cerebellar ataxia (loss of coordination and balance). MSA is often classified into two subtypes: MSA-P (Parkinsonian type), which resembles Parkinson's disease, and MSA-C (cerebellar type), which affects balance and coordination more prominently. The exact cause of MSA is unknown, but it involves abnormal accumulation of a protein called alpha-synuclein in the brain, leading to cell damage. Symptoms typically worsen over time, and the condition has no known cure. Management focuses on alleviating symptoms and improving quality of life, though treatments for the underlying disease are still under investigation.

Find out more about multiple system atrophy medication at https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Multiple System Atrophy Treatment Analysis: Drug Profile
Lu AF82422: H. Lundbeck A/S
Lu AF82422 is a human monoclonal antibody (mAb) designed to target and bind to all major forms of extracellular α-synuclein, thereby preventing its uptake and inhibiting aggregation. The antibody also has an active Fc region, which may enhance immune-mediated clearance of α-syn/mAb complexes via microglia-mediated uptake. Developed by Lundbeck under a joint research and licensing agreement with Genmab A/S, Lu AF82422 is currently being investigated in a Phase III clinical trial for patients with Multiple System Atrophy (MSA).

ATH434: Alterity Therapeutics
ATH434 is an oral therapeutic designed to inhibit the aggregation of pathological proteins involved in neurodegenerative diseases. It works as an iron chaperone, helping restore normal iron balance in the brain, and has demonstrated preclinical efficacy in reducing α-synuclein pathology and preserving neuronal function. ATH434 has shown positive results in Phase I trials, where it was well-tolerated and achieved brain levels similar to those seen in animal models. The drug is currently being studied in two Phase II clinical trials: Study ATH434-201, a randomized, double-blind, placebo-controlled trial in early-stage MSA patients, and Study ATH434-202, an open-label biomarker trial in more advanced MSA patients. ATH434 has received Orphan Drug Designation for MSA from both the US FDA and the European Commission.

Learn more about the novel and emerging multiple system atrophy pipeline therapies at https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Multiple System Atrophy Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Multiple System Atrophy Pipeline Report
• Coverage: Global
• Key Multiple System Atrophy Companies: Theravance Biopharma, Alterity Therapeutics, AskBio, Kainos Medicines, CORESTEM, Inc., ProMIS Neuroscience, H. Lundbeck A/S, and others.
• Key Multiple System Atrophy Pipeline Therapies: Ampreloxetine, ATH434, AB-1005, KM-819, Lu AF82422, CE111BR16, PMN442, and others.

To dive deep into rich insights for drugs used for multiple system atrophy treatment, visit: https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Multiple System Atrophy Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Multiple System Atrophy Pipeline Therapeutics
6. Multiple System Atrophy Pipeline: Late-Stage Products (Phase III)
7. Multiple System Atrophy Pipeline: Mid-Stage Products (Phase II)
8. Multiple System Atrophy Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Multiple System Atrophy Pipeline Insight 2025: 22+ Pipeline Drugs, Disease-Modifying Candidates, and Symptomatic Therapies Advancing Clinical Care | DelveInsight here

News-ID: 4186693 • Views:

More Releases from DelveInsight

Advanced Gastric Carcinoma Clinical Trials Analysis 2025: Targeted Agents, Immuno-Oncology Therapies, and Novel Combinations Aim to Improve Survival and Response Rates | DelveInsight
Advanced Gastric Carcinoma Clinical Trials Analysis 2025: Targeted Agents, Immun …
DelveInsight's "Advanced Gastric Carcinoma (AGC) - Clinical Trials Analysis, 2025" reviews a rapidly evolving clinical pipeline focused on enhancing overall survival, response durability, and tolerability in patients with unresectable or metastatic disease. Despite standard chemotherapy regimens forming the backbone of treatment, prognosis remains poor, with a high proportion of patients experiencing progression, creating a pressing need for innovative therapeutic options. The AGC pipeline is progressing with targeted therapies including HER2-directed agents,
Advanced Urothelial Carcinoma Clinical Trials Analysis 2025: Targeted Therapies, Immuno-Oncology Combinations, and Novel Checkpoint Inhibitors Aim to Enhance Survival and Patient Outcomes | DelveInsight
Advanced Urothelial Carcinoma Clinical Trials Analysis 2025: Targeted Therapies, …
DelveInsight's "Advanced Urothelial Carcinoma (aUC) - Clinical Trials Analysis, 2025" examines a dynamic pipeline focused on improving survival, response rates, and tolerability for patients with locally advanced or metastatic disease. Despite the availability of platinum-based chemotherapy and checkpoint inhibitors, a significant portion of patients experience disease progression or relapse, highlighting a critical unmet need for innovative treatments. The aUC clinical landscape is rapidly evolving, with next-generation targeted therapies, such as FGFR
Post-Polycythemia Vera Myelofibrosis Clinical Trials Analysis 2025: Novel JAK Inhibitors, Pathway-Targeted Agents, and Combination Approaches Aim to Address Unmet Needs | DelveInsight
Post-Polycythemia Vera Myelofibrosis Clinical Trials Analysis 2025: Novel JAK In …
DelveInsight's "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Clinical Trials Analysis, 2025" highlights an evolving pipeline designed to tackle the limitations of current therapies and improve long-term outcomes for patients with this rare secondary myeloproliferative neoplasm. While JAK inhibitors such as ruxolitinib and fedratinib remain the cornerstone of treatment, their benefits are primarily palliative, with limited disease-modifying activity. This gap has spurred innovation toward agents capable of reducing fibrosis, improving survival rates,
Immunologic Deficiency Syndrome Clinical Trials Analysis 2025: Gene Therapies, Next-Gen Ig Replacement, and Precision Immunomodulators Targeting Durable Immune Restoration | DelveInsight
Immunologic Deficiency Syndrome Clinical Trials Analysis 2025: Gene Therapies, N …
DelveInsight's "Immunologic Deficiency Syndrome - Clinical Trials Analysis, 2025" reviews the rapidly evolving clinical landscape for primary and selected secondary immunodeficiency disorders, a heterogeneous group of conditions characterized by impaired host defense and recurrent, sometimes life-threatening infections. While lifelong immunoglobulin replacement and hematopoietic stem cell transplant (HSCT) remain cornerstones for many patients, persistent unmet needs - including incomplete immune reconstitution, treatment burden, infection risk, and long-term complications - are driving

All 5 Releases


More Releases for Multiple

Mango AI's Multiple Face Swap Video Tool Changes Multiple Faces Instantly
In today's digital world, creating eye-catching and unique content is essential for standing out. The ability to swap multiple faces in a single video opens up creative possibilities, whether for personalized content, comedy or parody videos, or engaging social media posts. Mango AI, developed by Mango Animate, is excited to announce the launch of its advanced multiple face swap video (https://mangoanimate.com/ai/multiple-face-swap-video) tool, which is designed to simplify the creation of
Multiple Sclerosis Drugs Market
Global Multiple Sclerosis Drugs Market Size research report offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market. Get a Sample Copy of the Report at - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100386 Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as progressive brain and spinal cord atrophy and neuroaxonal
Massive Multiple Input Multiple Output (MIMO) Market May Set New Growth Story
A Latest intelligence report published by MR Forecast with title "Global Massive Multiple Input Multiple Output (MIMO) Market Outlook to 2032. A detailed study accumulated to offer Latest insights about acute features of the Massive Multiple Input Multiple Output (MIMO) market. This report provides a detailed overview of key factors in the Global Massive Multiple Input Multiple Output (MIMO) Market and factors such as driver, restraint, past and current trends,
Multiple Sclerosis Drugs Market - Progressing Towards a Cure: Advancing Multiple …
Newark, New Castle, USA: The "Multiple Sclerosis Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Multiple Sclerosis Drugs Market: https://www.growthplusreports.com/report/multiple-sclerosis-drugs-market/7983 This latest report researches the industry structure,
Multiple Sclerosis Drugs Market - Empowering Resilience, Embracing Possibilities …
Newark, New Castle, USA - new report, titled Multiple Sclerosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Multiple Sclerosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Multiple Sclerosis Drugs market. The report offers an overview of
Massive MIMO (Multiple-input multiple-output) Market 2022-2028 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Massive MIMO (Multiple-input multiple-output) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Massive MIMO (Multiple-input multiple-output) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Massive MIMO (Multiple-input multiple-output)